Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 4/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.42 |
| ▸ | RXRB | P28702 | 1/20 | 0.42 |
| ▸ | RXRG | P48443 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.40 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.40 |
| ▸ | TEAD2 | Q15562 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.37 |
| ▸ | ATR | Q13535 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29444527 | 1.00 | HCAR3 (0.43) | HCAR3RXRARXRBRXRGHSD17B10 | |
| SCHEMBL9904645 | 0.88 | PDE7A (0.38) | RXRARXRBRXRGCNR1CNR2 | |
| SCHEMBL30159627 | 0.88 | ALDH1A1 (0.41) | RXRARXRBRXRGHSD17B10KDM4E | |
| SCHEMBL9904651 | 0.88 | ALDH1A1 (0.41) | RXRARXRBRXRGHSD17B10KDM4E | |
| SCHEMBL10324481 | 0.85 | L3MBTL1 (0.44) | HCAR3RXRARXRBRXRGHSD17B10 | |
| SCHEMBL30040921 | 0.85 | L3MBTL1 (0.44) | HCAR3RXRARXRBRXRGHSD17B10 | |
| SCHEMBL17801039 | 0.85 | HCAR3 (0.43) | HCAR3RXRARXRBRXRGHSD17B10 | |
| SCHEMBL18393153 | 0.85 | CYP4F2 (0.41) | RXRARXRBRXRGGAAALDH1A1 | |
| SCHEMBL27032319 | 0.85 | ALDH1A1 (0.43) | HSD17B10GAAKDM4EALDH1A1HPGD | |
| SCHEMBL23535805 | 0.84 | CNR1 (0.45) | HCAR3RXRARXRBRXRGHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025106722-A1 | INHIBITORS OF STK33, RET, CLK, AND/OR RELATED KINASES AND METHODS USING SAME | BAYLOR COLLEGE OF MEDICINE (US) | 2025-05-22 | — | — | WO | disclosed |
| CN-108884096-B | Spiroindolinones as DDR1 inhibitors | 豪夫迈·罗氏有限公司 | 2022-03-22 | — | — | CN | disclosed |
| EP-3414247-B1 | SPIROINDOLINONES AS DDR1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2021-04-21 | — | — | EP | disclosed |
| US-10618897-B2 | Spiroindolinones as DDR1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2020-04-14 | — | — | US | disclosed |
| US-20190071444-A1 | SPIROINDOLINONES AS DDR1 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2019-03-07 | — | — | US | disclosed |
| EP-3414247-A1 | SPIROINDOLINONES AS DDR1 INHIBITORS | H. Hoffnabb-La Roche Ag (CH) | 2018-12-19 | — | — | EP | disclosed |
| WO-2017137334-A1 | SPIROINDOLINONES AS DDR1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2017-08-17 | — | — | WO | disclosed |
| US-9090593-B2 | Bicyclic compounds as Pim inhibitors | AMGEN INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-9090593-B2 | Bicyclic compounds as Pim inhibitors | AMGEN INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-20140031360-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140031360-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2014-01-30 | — | — | US | disclosed |
| EP-2649065-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | Amgen Inc. (US) | 2013-10-16 | — | — | EP | disclosed |
| WO-2012078777-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10618897-B2 | Spiroindolinones as DDR1 inhibitors | DDR1, DDR2, DDRGK1 | HCAR3 3968/4885RXRA 2261/4885RXRB 2036/4885 |
| US-20190071444-A1 | SPIROINDOLINONES AS DDR1 INHIBITORS | DDR1, DDR2, DDRGK1 | HCAR3 3968/4885RXRA 2261/4885RXRB 2036/4885 |
| US-20140031360-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | PIM1, PIM2, PIM3 | HCAR3 3662/4885RXRA 4266/4885RXRB 4402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.